Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
Eur J Health Econ
.
2014 Apr;15(3):223-8.
doi: 10.1007/s10198-013-0538-4.
Epub 2013 Nov 23.
Authors
María-Isabel Farfan-Portet
1
,
Sophie Gerkens
,
Isabelle Lepage-Nefkens
,
Irmgard Vinck
,
Frank Hulstaert
Affiliation
1
Belgian Health Care Knowledge Centre, Boulevard du Botanique, 50, 1000, Brussels, Belgium, maria.farfan@kce.fgov.be.
PMID:
24271016
PMCID:
PMC3950601
DOI:
10.1007/s10198-013-0538-4
No abstract available
Publication types
Editorial
Review
MeSH terms
Biosimilar Pharmaceuticals / economics*
Cost Control
Economic Competition / economics*
Europe
Fees, Pharmaceutical*
Humans
Substances
Biosimilar Pharmaceuticals